{"id":"methylprednisolone-or-equivalent","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia and mood changes"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Cushingoid features (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylprednisolone acts as a potent immunosuppressant and anti-inflammatory agent by binding intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. It is commonly used as a reference standard for corticosteroid potency comparisons.","oneSentence":"Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:59.913Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Adrenal insufficiency"},{"name":"Cerebral edema"},{"name":"Multiple sclerosis relapse"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07197749","phase":"EARLY_PHASE1","title":"Vitamin C With Steroids for Gastrointestinal GVHD","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"Graft-versus-host-disease (GVHD), Gastrointestinal","enrollment":35},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT07199192","phase":"PHASE4","title":"Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-03-01","conditions":"Hypoxemia, Severe Acute Respiratory Syndrome","enrollment":3000},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT03384277","phase":"PHASE4","title":"Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-12-29","conditions":"Acquired Hemophilia A","enrollment":66},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":769},{"nctId":"NCT07267650","phase":"NA","title":"iPACK Block vs. Periarticular Infiltration for TKA Pain Control","status":"NOT_YET_RECRUITING","sponsor":"Turgutlu State Hospital","startDate":"2026-01-01","conditions":"Pain, Postoperative, Osteoarthritis, Knee / Osteoarthritis, Hip","enrollment":100},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT03952286","phase":"PHASE4","title":"ED-Initiated School-based Asthma Medication Supervision","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2019-08-01","conditions":"Asthma, Asthma in Children","enrollment":13},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT03721965","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-12-31","conditions":"Acute Graft-versus-host Disease","enrollment":2},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT06598332","phase":"EARLY_PHASE1","title":"5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2025-08","conditions":"Graft-Versus-Host Disease(GVHD)","enrollment":""},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT05714930","phase":"NA","title":"LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-12-12","conditions":"Systemic Lupus Erythematosus","enrollment":606},{"nctId":"NCT06471465","phase":"PHASE3","title":"Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-04-29","conditions":"Radionecrosis of Brain, Brain Metastases","enrollment":84},{"nctId":"NCT06172361","phase":"PHASE3","title":"Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Polymyalgia Rheumatica","enrollment":98},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT03542279","phase":"NA","title":"CPI Combination Therapy for Autoimmune Encephalitis","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-11-25","conditions":"Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT03811366","phase":"NA","title":"Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06-01","conditions":"Uveomeningoencephalitic Syndrome, Inflammation, Choroid Disease","enrollment":12},{"nctId":"NCT05567289","phase":"","title":"Precision Medicine for Stem Cell Transplantation","status":"RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-06","conditions":"Haematopoietic Stem Cell Transplantation","enrollment":300},{"nctId":"NCT06223074","phase":"PHASE2","title":"Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration","status":"ENROLLING_BY_INVITATION","sponsor":"Universidad Nacional Autonoma de Mexico","startDate":"2023-01-09","conditions":"Multiple Sclerosis Relapsing Remitting, Treatment","enrollment":80},{"nctId":"NCT05707156","phase":"","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-07-05","conditions":"Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis","enrollment":12032},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT05401812","phase":"PHASE2","title":"Glucocorticoid Therapy for Acute Respiratory Distress Syndrome","status":"WITHDRAWN","sponsor":"National Taiwan University Hospital","startDate":"2022-07-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT04660539","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":119},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT03817853","phase":"PHASE4","title":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-26","conditions":"Advanced Follicular Lymphoma","enrollment":114},{"nctId":"NCT03298061","phase":"PHASE3","title":"Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-14","conditions":"Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT06266221","phase":"PHASE3","title":"Severe Erythema Multiforme - CORTICO","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-05-01","conditions":"Erythema Multiforme","enrollment":96},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT04054375","phase":"PHASE2","title":"Weekly Steroids in Muscular Dystrophy","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-07-01","conditions":"Limb-girdle Muscular Dystrophy, Becker Muscular Dystrophy","enrollment":20},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT05604859","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)","status":"UNKNOWN","sponsor":"Qin Ning","startDate":"2022-08-19","conditions":"Severe Fever With Thrombocytopenia Syndrome","enrollment":350},{"nctId":"NCT02798523","phase":"PHASE1","title":"Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-24","conditions":"Normal Physiology","enrollment":33},{"nctId":"NCT02425852","phase":"PHASE4","title":"A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2016-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT00323960","phase":"PHASE3","title":"Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2006-05-31","conditions":"Juvenile Dermatomyositis","enrollment":139},{"nctId":"NCT01086540","phase":"PHASE2","title":"Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-24","conditions":"Systemic Sclerosis-Associated PAH","enrollment":57},{"nctId":"NCT05648734","phase":"","title":"Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-03-10","conditions":"Post-COVID-19 Syndrome, Lung Fibrosis","enrollment":200},{"nctId":"NCT02133924","phase":"PHASE2","title":"Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"John Levine","startDate":"2016-08","conditions":"Acute Graft Versus Host Disease","enrollment":76},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT02442180","phase":"PHASE3","title":"Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid","status":"TERMINATED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2015-07","conditions":"Alcoholic Hepatitis","enrollment":64},{"nctId":"NCT04874610","phase":"","title":"Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-08-16","conditions":"Pediatric Obesity, Asthma in Children","enrollment":15},{"nctId":"NCT03632187","phase":"PHASE3","title":"Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2018-12-13","conditions":"Polymyalgia Rheumatica","enrollment":34},{"nctId":"NCT03853044","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-12-29","conditions":"Angioimmunoblastic T-cell Lymphoma","enrollment":23},{"nctId":"NCT03465527","phase":"PHASE2","title":"Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2017-04-13","conditions":"Diffuse Large B Cell Lymphoma","enrollment":37},{"nctId":"NCT05135442","phase":"PHASE4","title":"Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-12-01","conditions":"Thrombotic Thrombocytopenic Purpura, Acquired","enrollment":30},{"nctId":"NCT03852537","phase":"PHASE2","title":"Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-12-02","conditions":"Pneumonia","enrollment":44},{"nctId":"NCT04485429","phase":"PHASE3","title":"Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"D'Or Institute for Research and Education","startDate":"2020-07-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT03708718","phase":"PHASE2","title":"Prednisolone in Early Diffuse Systemic Sclerosis","status":"COMPLETED","sponsor":"Prof. Ariane herrick","startDate":"2017-12-21","conditions":"Systemic Sclerosis","enrollment":35},{"nctId":"NCT01790594","phase":"PHASE2","title":"Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-02","conditions":"Simultaneous Kidney and Pancreas Transplantation","enrollment":46},{"nctId":"NCT04762784","phase":"PHASE4","title":"A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-01","conditions":"Idiopathic Retroperitoneal Fibrosis","enrollment":40},{"nctId":"NCT04762810","phase":"PHASE4","title":"A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-03","conditions":"Idiopathic Retroperitoneal Fibrosis","enrollment":40},{"nctId":"NCT02365077","phase":"","title":"GWAS Identified Susceptibility Loci for Glucocorticoid-induced FHN in the Chinese Population","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2015-01-01","conditions":"Femur Head Necrosis, Adverse Effect of Glucocorticoids and Synthetic Analogues","enrollment":2500},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT02956122","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2017-04-26","conditions":"Graft Versus Host Disease","enrollment":1},{"nctId":"NCT04660565","phase":"PHASE4","title":"Belimumab Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01","conditions":"IgG4-related Disease","enrollment":60},{"nctId":"NCT02462252","phase":"PHASE2","title":"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2015-10","conditions":"Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome","enrollment":11},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT04559113","phase":"NA","title":"Methylprednisolone in COVID-19 Patients (Methyl19LGH)","status":"UNKNOWN","sponsor":"Lahore General Hospital","startDate":"2020-05-01","conditions":"SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)","enrollment":200},{"nctId":"NCT02260934","phase":"PHASE2","title":"Rituximab and Belimumab for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-09","conditions":"Lupus Nephritis","enrollment":43},{"nctId":"NCT02935738","phase":"NA","title":"Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies","status":"COMPLETED","sponsor":"Barz IVF Center for Infertility Treatment and Embryo Research","startDate":"2014-10","conditions":"Reproductive Sterility","enrollment":241},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT00485589","phase":"PHASE3","title":"A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-06-11","conditions":"Rheumatoid Arthritis","enrollment":613},{"nctId":"NCT03133897","phase":"PHASE3","title":"Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study","status":"TERMINATED","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2018-03-05","conditions":"Asthma","enrollment":20},{"nctId":"NCT01445821","phase":"PHASE3","title":"Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2011-09-15","conditions":"Scleroderma, Systemic","enrollment":44},{"nctId":"NCT04458636","phase":"PHASE4","title":"Stratified TreAtment to Reduce Risk in COPD","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-11-02","conditions":"COPD Exacerbation","enrollment":203},{"nctId":"NCT00263562","phase":"PHASE3","title":"Steroid Treatment for Sickle Cell Pain Crisis","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2005-12-01","conditions":"Sickle Cell Disease, Vaso-occlusive Crisis","enrollment":18},{"nctId":"NCT03584802","phase":"NA","title":"Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-05-16","conditions":"Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":40},{"nctId":"NCT01892488","phase":"PHASE4","title":"Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2013-06-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":295},{"nctId":"NCT02176031","phase":"PHASE2","title":"Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"Graft Versus Host Disease","enrollment":21},{"nctId":"NCT00504348","phase":"PHASE2, PHASE3","title":"Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus","status":"COMPLETED","sponsor":"Tokyo Medical and Dental University","startDate":"2007-07","conditions":"Interstitial Pneumonitis, Polymyositis, Dermatomyositis","enrollment":25},{"nctId":"NCT04273581","phase":"PHASE2","title":"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-18","conditions":"COVID-19 Thalidomide","enrollment":40},{"nctId":"NCT01287741","phase":"PHASE3","title":"A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-26","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1418},{"nctId":"NCT01381874","phase":"PHASE2","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-24","conditions":"Metastatic ER+ Her2- Breast Cancer, Postmenopausal","enrollment":297}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":307282,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methylprednisolone or equivalent","genericName":"Methylprednisolone or equivalent","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Polymyalgia rheumatica.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}